A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

Data on 1711 patients, aged up to 55 years, in the MRC AML 10 trial were used to create a prognostic index for use in risk‐directed therapy decision making for younger patients with acute myeloid leukaemia (AML). Two parameters, response after course 1 and cytogenetics, were strongly predictive of o...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 1999-10, Vol.107 (1), p.69-79
Main Authors: Wheatley, Keith, Burnett, Alan K., Goldstone, Anthony H., Gray, Richard G., Hann, Ian M., Harrison, Christine J., Rees, John K. H., Stevens, Richard F., Walker, Helen
Format: Article
Language:English
Subjects:
acute myeloid leukaemia
Biological and medical sciences
cytogenetics
Hematologic and hematopoietic diseases
Hematology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
prognostic index
response
risk‐directed therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Data on 1711 patients, aged up to 55 years, in the MRC AML 10 trial were used to create a prognostic index for use in risk‐directed therapy decision making for younger patients with acute myeloid leukaemia (AML). Two parameters, response after course 1 and cytogenetics, were strongly predictive of outcome. For patients with complete remission, partial remission and resistant disease, 5‐year survival from the start of course 2 was 53%, 44% and 22% and relapse rates were 46%, 48% and 69% respectively, and for patients with favourable, intermediate and adverse karyotypic abnormalities, survival was 72%, 43% and 17% and relapse rates were 34%, 51% and 75% respectively (all P 
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.1999.01684.x